Glaxo SmithKline
Last Updated:
- 43.08 EGP
- -0.50
- -1.15%
جلاكسو سميثكلاين
جلاكسو سميثكلاين
Symbol :
BIOC
ISIN :
EGS38171C012
52-Week Range :
24.70
-
47.50
Turnover Ratio :
0.25
Market :
Egyptian Exchange
Sector :
Real Estate
Industry :
Pharmaceuticals and Biotechnology Research & Development
Sub-Industry :
Basic Information
-
Activity :Glaxo SmithKline is a public company, listed on Egyptian Exchange (EGX) since October 1985. It operates within the Pharmaceuticals, Biotechnology and Life Sciences sector focusing on Pharmaceuticals. Glaxo...
-
Industry Group :pharmaceuticals Research and Biotechnology
-
Sub-Industry :
-
ISIN :EGS38171C012
-
Contact Person :
-
Established On:14-Jan-1981
-
Stock Listing On :23-Oct-1985
-
No of Employees :775 Employees as of 2022
-
Outstanding Shares :83,514,200
-
Free Float Shares :
-
Par Value :
-
Paid Capital :
-
Market Cap :
-
Authorized Capital :
Indices Membership
| Action | Date | Index | Provider |
|---|---|---|---|
| Leave | 2024 | EGX100 EWI | Egyptian Exchange |
| Leave | 2024 | EGX70 EWI Index | Egyptian Exchange |
| Join | 2024 | EGX100 EWI | Egyptian Exchange |
| Join | 2024 | EGX70 EWI Index | Egyptian Exchange |
| Join | 2024 | Real Estate | Egyptian Exchange |
| Leave | 2024 | EGX100 EWI | Egyptian Exchange |
| Leave | 2024 | EGX70 EWI Index | Egyptian Exchange |
| Join | 2023 | EGX100 EWI | Egyptian Exchange |
| Join | 2023 | EGX70 EWI Index | Egyptian Exchange |
| Join | 2020 | Health Care & Pharmaceuticals | Egyptian Exchange |
| Leave | 2011 | EGX 70 | Egyptian Exchange |
| Join | 2011 | EGX 70 | Egyptian Exchange |
| Leave | 2010 | EGX 70 | Egyptian Exchange |
| Join | 1985 | Egyptian Exchange |
| Glaxo SmithKline |
| Boomerang Buliding, New Cairo, Cairo, P.O. Box 41. |
| T : +20 2 26185000 |
| F : +20 2 26185001 |
| www.gsk.com/en-gb/contact-us/worldwide/egypt/ |
| mohsen.x.bebawy@gsk.com |
Management
| Title | Name | As Of |
|---|---|---|
| Chairman: | Ahmed Khattab | |
| Managing Director: | Hassan Fahmy | |
| Board Member: | Munir Hanna | |
| Omnia Kelig | 2021 | |
| Shirin Al Ansary | ||
| Laila Boles | ||
| Mohammad Abdul Azim | ||
| Omar Shoukry | ||
| Vikas Jan |
Reports
| Date | Title | File |
|---|---|---|
| 2024 | Glaxo SmithKline Non- consolidated Quarterly Financials Report Q2 2024 | |
| 2024 | Glaxo SmithKline Quarterly Financials Report Q2 2024 | |
| 2024 | Glaxo SmithKline Quarterly Financials Report Q1 2024 | |
| 2024 | Glaxo SmithKline Non- consolidated Quarterly Financials Report Q1 2024 | |
| 2024 | Glaxo SmithKline Annual Financials Report 2023 | |
| 2024 | Glaxo SmithKline Non- consolidated Annual Financials Report 2023 | |
| 2024 | Glaxo SmithKline Annual Financials Report 2023 | |
| 2023 | Glaxo SmithKline Quarterly Financials Report Q3 2023 | |
| 2023 | Glaxo SmithKline Non- consolidated Quarterly Financials Report Q3 2023 | |
| 2023 | Glaxo SmithKline Quarterly Financials Report Q2 2023 | |
| 2023 | Glaxo SmithKline Non- consolidated Quarterly Financials Report Q2 2023 |
